Koers Bachem Holding AG Swiss Exchange
Aandelen
BANB
CH0012530207
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 620 mln. 674 mln. 631 mln. | Omzet 2025 * | 811 mln. 881 mln. 825 mln. | Marktkapitalisatie | 6,01 mld. 6,53 mld. 6,12 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 127 mln. 138 mln. 129 mln. | Nettowinst (verlies) 2025 * | 160 mln. 174 mln. 163 mln. | EV/omzet 2024 * | 9,59 x |
Nettoliquiditeiten 2024 * | 64,89 mln. 70,53 mln. 66,04 mln. | Nettoschuld 2025 * | 74,85 mln. 81,34 mln. 76,17 mln. | EV/omzet 2025 * | 7,5 x |
K/w-verhouding 2024 * |
50
x | K/w-verhouding 2025 * |
37,9
x | Werknemers | 2.006 |
Dividendrendement 2024 * |
1,07% | Dividendrendement 2025 * |
1,16% | Vrij verhandelbaar | 94,31% |
Recentste transcriptie over Bachem Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 01-01-19 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 01-02-21 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 25-04-12 |
Director/Board Member | 51 | 13-04-11 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.15% | 18 M€ | +2,87% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,30% | 42,19 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,61% | 24,63 mld. | |
-23,40% | 18,2 mld. | |
+26,81% | 12,01 mld. | |
-3,17% | 11,76 mld. | |
+14,03% | 10,4 mld. | |
-3,81% | 9,94 mld. |